Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Laux

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
International Journal of Psychiatry in Clinical Practice|February 11, 2014
Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naïve patients, in combination therapy and after treatment switchGerd Laux, Nadja A Huttner,
Psychiatrische Praxis|September 18, 2003
[Neuroleptics and Cognition]Alexander Brunnauer, Elisabeth Geiger, Gerd Laux
Der Nervenarzt|April 23, 2026
[Mental diseases and driving ability-An update]Alexander Brunnauer, Peter Zwanzger, Gerd Laux
Psychiatrische Praxis|December 1, 2004
[Antipsychotics and memory functions in schizophrenic patients]Alexander Brunnauer, Elisabeth Geiger, Gerd Laux
European Archives of Psychiatry and Clinical Neuroscience|July 14, 2009
Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychoticsAlexander Brunnauer, Gerd Laux, Sarah Zwick
Psychiatrische Praxis|December 1, 2004
[QTc-interval prolongation in therapy with atypical antipsychotics--results of an open, non-randomized survey]Martin Finzel, Mirijam Fric, Gerd Laux
Psychiatrische Praxis|September 26, 2003
[Neuroleptics and cognition]Alexander Brunnauer, Elisabeth Geiger, Gerd Laux
Psychiatrische Praxis|December 1, 2004
[Erythema multiforme caused by carbamazepine]Carsten Steinmann, Mirijam Fric, Gerd Laux
Clinical Neuropharmacology|March 5, 2019
The Dopamine Receptor Antagonism of Opipramol: Relevance to Parkinsonism?Verena Rozanski, Gerd Laux, Johannes Schwarz
Neurotoxicity Research|June 17, 2010
Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?Peter Riederer, Jasmin Bartl, Gerd Laux, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
International Journal of Psychiatry in Clinical Practice|February 11, 2014
Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naïve patients, in combination therapy and after treatment switchGerd Laux, Nadja A Huttner,
Psychiatrische Praxis|September 18, 2003
[Neuroleptics and Cognition]Alexander Brunnauer, Elisabeth Geiger, Gerd Laux
Der Nervenarzt|April 23, 2026
[Mental diseases and driving ability-An update]Alexander Brunnauer, Peter Zwanzger, Gerd Laux
Psychiatrische Praxis|December 1, 2004
[Antipsychotics and memory functions in schizophrenic patients]Alexander Brunnauer, Elisabeth Geiger, Gerd Laux
European Archives of Psychiatry and Clinical Neuroscience|July 14, 2009
Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychoticsAlexander Brunnauer, Gerd Laux, Sarah Zwick
Psychiatrische Praxis|December 1, 2004
[QTc-interval prolongation in therapy with atypical antipsychotics--results of an open, non-randomized survey]Martin Finzel, Mirijam Fric, Gerd Laux
Psychiatrische Praxis|September 26, 2003
[Neuroleptics and cognition]Alexander Brunnauer, Elisabeth Geiger, Gerd Laux
Psychiatrische Praxis|December 1, 2004
[Erythema multiforme caused by carbamazepine]Carsten Steinmann, Mirijam Fric, Gerd Laux
Clinical Neuropharmacology|March 5, 2019
The Dopamine Receptor Antagonism of Opipramol: Relevance to Parkinsonism?Verena Rozanski, Gerd Laux, Johannes Schwarz
Neurotoxicity Research|June 17, 2010
Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?Peter Riederer, Jasmin Bartl, Gerd Laux, et al.
Pageof 10